Macitentan PAH

Phase 2

• Conditions: Pulmonary arterial hypertension (PAH)

• Registration Number: JPRN-jRCT2080221941
• Lead Sponsor: ippon Shinyaku co.,LTD./Actelion Pharmaceuticals Japan Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-10-17
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Idiopathic PAH (IPAH);
- Heritable PAH (HPAH);
- Drug- or toxin-induced PAH; or
- PAH associated with:
a) Connective tissue disease; or
b) Simple, congenital systemic-to-pulmonary shunts at least 1 year post surgical repair

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified